BioCardia已向美国食品药品监督管理局（FDA）提交了Helix™经心内膜输送导管的上市前申请。该导管旨在将治疗性和诊断性药物精准递送至心脏靶向区域。
BioCardia已向美国食品药品监督管理局（FDA）提交了Helix™经心内膜输送导管的上市前申请。该导管旨在将治疗性和诊断性药物精准递送至心脏靶向区域。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.